Publications
Detailed Information
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial : Sacituzumab govitecan in HR<SUP>+</SUP>HER2<SUP>-</SUP> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xu, Binghe | - |
dc.contributor.author | Wang, Shusen | - |
dc.contributor.author | Yan, Min | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Li, Wei | - |
dc.contributor.author | Tang, Jinhai | - |
dc.contributor.author | Wang, Xiaojia | - |
dc.contributor.author | Wang, Ying | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Jiang, Dongdong | - |
dc.contributor.author | Valdez, Theresa | - |
dc.contributor.author | Dasgupta, Anandaroop | - |
dc.contributor.author | Zhang, Yiran | - |
dc.contributor.author | Yan, Yilin | - |
dc.contributor.author | Komatsubara, Kimberly M. | - |
dc.contributor.author | Chung, Wei-Pang | - |
dc.contributor.author | Ma, Fei | - |
dc.contributor.author | Dai, Ming-Shen | - |
dc.date.accessioned | 2024-12-11T06:49:12Z | - |
dc.date.available | 2024-12-11T06:49:12Z | - |
dc.date.created | 2024-12-11 | - |
dc.date.created | 2024-12-11 | - |
dc.date.created | 2024-12-11 | - |
dc.date.created | 2024-12-11 | - |
dc.date.issued | 2024-12 | - |
dc.identifier.citation | Nature Medicine, Vol.30 No.12, pp.3709-3716 | - |
dc.identifier.issn | 1078-8956 | - |
dc.identifier.uri | https://hdl.handle.net/10371/213589 | - |
dc.description.abstract | Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR(+)HER2(-)) metastatic breast cancer (mBC) in the global TROPiCS-02 study. TROPiCS-02 enrolled few Asian patients. Here we report results of SG in Asian patients with HR(+)HER2(-) mBC from the EVER-132-002 study. Patients were randomized to SG (n = 166) or chemotherapy (n = 165). The primary endpoint was met: PFS was improved with SG versus chemotherapy (hazard ratio of 0.67, 95% confidence interval 0.52-0.87; P = 0.0028; median 4.3 versus 4.2 months). OS also improved with SG versus chemotherapy (hazard ratio of 0.64, 95% confidence interval 0.47-0.88; P = 0.0061; median 21.0 versus 15.3 months). The most common grade >= 3 treatment-emergent adverse events were neutropenia, leukopenia and anemia. SG demonstrated significant and clinically meaningful improvement in PFS and OS versus chemotherapy, with a manageable safety profile consistent with prior studies. SG represents a promising treatment option for Asian patients with HR(+)HER2(-) mBC (ClinicalTrials.gov identifier no. NCT04639986). | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial | - |
dc.title.alternative | Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1038/s41591-024-03269-z | - |
dc.citation.journaltitle | Nature Medicine | - |
dc.identifier.wosid | 001326615500001 | - |
dc.identifier.scopusid | 2-s2.0-85205513353 | - |
dc.citation.endpage | 3716 | - |
dc.citation.number | 12 | - |
dc.citation.startpage | 3709 | - |
dc.citation.volume | 30 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ANTIBODY-DRUG CONJUGATE | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.